IGA Glomerulonephritis Clinical Trial
OBJECTIVES: I. Determine the most sensitive outcome measures (functional or morphological)
of a progressive renal injury in patients with IgA nephropathy.
II. Determine which of these patients are destined to progress to further injury in order to
target them for therapy.
III. Elucidate the determinants of progression in those patients who exhibit evidence of
either increasing impairment of ultrafiltration capacity or ongoing destruction of nephrons.
PROTOCOL OUTLINE: Patients receive oral enalapril daily. Treatment continues for 5 years in
the absence of unacceptable toxicity.
Patients undergo renal function studies every 6-12 months for 5 years. Patients undergo
renal biopsy at 36-48 months after study entry.
;
Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00004448 -
Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy
|
Phase 2 | |
| Completed |
NCT01560052 -
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
|
N/A | |
| Completed |
NCT02527902 -
Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy
|
N/A | |
| Completed |
NCT00004305 -
Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis
|
N/A | |
| Completed |
NCT01115426 -
Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
|
Phase 4 |